MYD88 and gestational diabetes: SIN has therapeutic effects in streptozotocin-induced gestational diabetes mellitus (GDM) rats with high safety, which is associated with the inhibition of inflammation and oxidative stress via the TLR4/MyD88/NF-κB signaling pathway (130).